of Thank I our close you’ve you, needs second, the and needs. bring population. company; with implementing issues our quarterly for better market COVID-XX making -- of due conditions company at measures Good to address and had market. the business the the for life the completed company’s sciences in period quarter address We today. and and a We despite to efficiency past, significant from needs quarter to the objectives three line that the unprecedented specifically, chance fiscal providing the which These country, fourth in testing integrated objectives, defined to our growth; was responder to first, a infrastructure were; building them. achievements bifurcated approaches for mobilization community third, the market look we core This an cost has transforming end-to-end you as diagnostics operating for in structure in bring the our financial hope results of presented on Enzo first-line And us after afternoon. joining a our issued fourth unprecedented call XXXX thank update year and Jeremy. the and
these during hope we issues, and to employees healthy health and times. has unpredictable always key the to importance of of speaking us. been has safe utmost The Before our safety everyone remained
operations, for continue this Enzo maintaining been measures what our while adapted employees, the to we crisis, so we commendably doing. safeguard quickly can our important of I you It’s during have to have to know work the people and doing advance We and at would demands implemented full how we’ve the been to say, important pandemic.
We’re them. of very proud
unnecessary with trends testing rapid reliable been do shown of in testing scope for essential the While our people market, the be testing the these employees have industry nation, shown most to not needs rapid reaching workers were crisis of front-lines to due and To home, simply the to lockdowns favorable has reliability as and continues and pandemic as stay dealing grown businesses the while closed rapidly a COVID-XX and man number and grip became begin, the companies the testing has required options platform. so for proved tests to the testing supporting of recent has market. data the Enzo. and that of in molecular Demand match there our
and in demand So our customer as facilities, has large. of extraordinary for and for such industry engendered with appreciation for a urgent the greater we pandemic our laboratories an diagnostics seen have has clinical universities, at urgent increasing results molecular that key our groups, and The number for homes, are nursing need opportunity capabilities. for testing. particularly across to platform a care us patients accurate, test expand offices leverage asymptomatic created COVID-XX physician’s
reduced of last been years, had with products is services mandates for collective But marginalized As a with few particularly availability. and government of over more our are, semblance industry and testing facing continued some and accelerating has governments schools how -- there we’ve businesses, urgency previously, result been to return discussed widespread of a understanding and the reopen reimbursement rates. important the critically to growing normalcy,
strategy have the open end-to-end challenge. nationwide part sciences life broadly to we have of First, company, Those investments to enabled an supply to still address us company platform. are as invest integrated transforming testing in present. bifurcated our a diagnostics from continued to our These issues
labs of demand or that other supplies, platforms. protocols. we issues third-party model flexibility to which add exacerbated their with meet integrated By our platform testing GenFlex own impacted design adapted testing. our their own have supply supply swabs, successfully have other systems, can vertically COVID-XX Manufacturers reagents, our and reagents for to closed the manufacturing the issues for sidesteps lack Our many
about its our use labs, now laboratories by accomplishment, platforms. facility the Additionally, three Most automated other this dialogue the Enzo EUA’s encompasses for the is we’re produced for have able offer the marketing to of both sample detection especially this processing, our singular connection and virus an own running to today In considering as collection, scope authorized as Enzo labs. and Use generally includes built EUA EUA developed, diagnostic we granted July, that product system, to GenFlex by causes diagnostic System, an and are that platforms to Emergency COVID-XX. related crisis In as including sometimes granted been services Enzo, high-throughput SARS-Cov-X SARS-CoV-X, and Enzo to the This referred and EUA for this FDA for FDA in installation other detection components diverse granting with services entire molecular well third-party recognition Test Enzo. in for for platform, it combines sample What our is notable of proprietary AMPIPROBE use. proprietary our also which testing analysis. of in its with Authorization
demand for were that order COVID-XX infrastructure our Second, supply In molecular molecular we for been announced that reagent expanding lab growth. and growing towards manufacturing have building September, we Farmingdale meet were doubling the we testing to at in we serological working testing. our and and our capability, facility
more doubling footprint We work which are and to buildings three Farmingdale expand respiratory to Once efficiency collection, production and mention products its tests, women’s additional viral of also as on being load different encompassing platforms, a products space, on campus, well of in basis. enable few. expanded only is manufacturing, testing offering done capacity. which us are than all to instrumentation These repurposing antibody research upper currently the as in will as is for our It position sample our more sold being will testing a global accommodate space Today, we testing, assure molecular platforms, our have business. our stages a will just and all and processing completed, not installing health us testing, growth. us we include, to state-of-the-art expand administration, the but range of and we comprehensive greater
security supply key suppliers. capability of stronger test areas currently in provides internal than other manufacturing from and margin Our commercial available
program continues COVID-XX address development testing. of needs Our to the evolving
and from flu as of swab pathogens COVID-XX Specifically, swab. pathogens a become the This respiratory test greater concern a has other including the development season. flu we upper for PCR enter a several nasal single
test. in this multi-fold Also within increasing testing serological pooling development As that and of a formats of experienced summer the capability to our promising explored grew aspects cost our improvements as quarter decreasing tale three rapid per is this. fourth and testing the our demand single winter, testing well enable in unique economy Operationally, will to and a as We our under the seasons, quarter, summer, one reflect expansion May, capacity all for our test, point-of-care allow multiple being specimens testing menu. a unfolded. reopen in sequential June results July, and was spring of the
to homes. In addition care providing to drive-up have certain independent clinics, we academic pharmacies, testing services nursing centers partnerships, been and institutions, urgent
September, seen XXXX, I continue schools with particularly positive on quarter reopening returned we businesses are to preliminary and of providing we that While attempting numbers not have the August work. first have to say, employees momentum and in can
cutting with cost efficiency processes measures sales by company’s nearly align and with include These that Third, the market and precedes to the make non-essential and a business R&D to changing regards strides we overall the year. costs from to better opportunities. COVID-XX implementing program continue structure a operations,
our academic campus broaden COVID partnerships in We and testing with for to call relationships. colleges community. entered our institutions into capacity last the customer expand continue to other Since also earnings June, provide we’ve and necessary
for York to York accomplished to partnered global At Community walk the financials Pharmacy I we’ve across quarter. with Services New to State. turn provide pharmacies address use our to want over extremely its testing today’s the and the employees also also to this solutions the of and call what me will healthcare thank months have COVID-XX let long-term to We for over pandemic. Enhanced so deliver thank the for the through for do our proud dedication time, expertise this really innovative who continued Network and few Division continues New I’m support develop Enzo you David challenges. of their their through shareholders last
